title: Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
authors.forename: Nicola
authors.initials: N
authors.lastname: Fazio
authors.forename: Roberto
authors.initials: R
authors.lastname: Biffi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Curigliano
authors.forename: Katia
authors.initials: K
authors.lastname: Lorizzo
authors.forename: Maria Giulia
authors.initials: MG
authors.lastname: Zampino
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
authors.forename: Antonio
authors.initials: A
authors.lastname: Chiappa
authors.forename: Arnaud
authors.initials: A
authors.lastname: Roth
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil